Neurolixis launches NLX-112 drug formulation collaboration with GALA laboratory in France
DANA POINT, Calif. - Feb. 20, 2019 - PRLog -- Neurolixis launched a collaboration with the GALA® laboratory in Castres, France. GALA® is a platform of the Rapsodee/IMT Mines Albi research facility specialized in developing novel drug formulations. GALA® has experimental tools and skills across a wide range of drug formulation technologies.
The Neurolixis-GALA collaboration focuses on the development of a novel formulation of NLX-112. This compound is in clinical development for treatment of dyskinesia (abnormal movements) seen in patients suffering from Parkinson's disease. The new formulation of NLX-112 will optimize its anti-dyskinetic activity and facilitate its administration to patients. The development of NLX-112 has been supported by grants from the Michael J. Fox Foundation, (USA) and Parkinson's UK. The Neurolixis-GALA collaboration is financed by subsidies from the Occitanie Region in France.
Adrian Newman-Tancredi, PhD, DSc, Chief Scientific Officer of Neurolixis, commented: "The development of a novel formulation of NLX-112 will be strong asset for the project and enable Parkinson's disease patients (about 1 million in the USA) to maximally benefit from this innovative treatment."
NLX-112 (also known as befiradol) acts on the brain's serotonin system, and is a particularly selective, high-efficacy agonist at 5-HT1A receptors. By targeting these receptors on serotonergic neurons, NLX-112 inhibits LID. NLX-112 is an orally-administered agent that has previously been tested in over 500 human subjects and Neurolixis plans to investigate its ability to reverse LID in patients with Parkinson's disease later this year.
About L-DOPA-induced Dyskinesia (LID)
LID are involuntary movements without purpose that commonly occur in Parkinson's patients after several years of treatment with dopamine replacement therapies such as L-DOPA. LID can become severely disabling, with patients often unable to perform routine daily tasks. As Parkinson's disease advances, the symptoms of LID worsen in frequency and severity. The presence of LID can restrict the dosing of L-DOPA, which may result in inadequate control of parkinsonian symptoms. The effective treatment of LID remains a high unmet need in the Parkinson's community.
Neurolixis is a privately held biotechnology company developing therapies for disorders of the central nervous system. The Company has two clinical programs: NLX-112 is a Phase 2-ready program targeting LID, and NLX-101 is a Phase 1 drug candidate targeting Rett syndrome. Additional discovery programs are targeting psychiatric disorders such as depression and schizophrenia.
Further information is available at http://www.neurolixis.com.
Dr Mark Varney, CEO Neurolixis,